Advertisement

Life-Sciences-Europe.com
The European Life Sciences Web Portal
This is a free web portal for the life sciences in Europe and Israel... » read more
- Novartis Acquires Anthos for up to $3.1b, with $925m Upfront (2025-02-11)
> Anthos Therapeutics is a clinical-stage biopharmaceutical company developing abelacimab, a potential first-in-class monoclonal antibody targeting the FXI inhibition pathway > Abelacimab is currently in Phase 3 development, with the lead indication for preventi... - Merck Confirms Discussions on Acquisition of SpringWorks Tx (2025-02-10)
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014 Merck KGaA (“Merck”) reacts to press reports and confirms advanced discussions with SpringWorks Therapeutics, Inc.. Merck also confirms that no legally binding ag... - Bain Capital to Acquire Mitsubishi Tanabe Pharma for $3.3b (2025-02-07)
Independent company plans significant investment in innovation, both internal product development and external licensing and acquisitions, supported by Bain Capital investment Bain Capital, a leading global private investment firm, today announced it has signe... - HTGF: Avelios Medical’s €30m Series A Led by Sequoia Capital (2025-02-06)
> The funding round is one of the largest Series A rounds in digital health in recent months. > Avelios Medical offers the HIS of the future: designed around hospital workflows, powered by modular microservices, and based on structured data to enable AI-driven c... - BD Intents to Separate Biosciences & Diagnostics Business (2025-02-05)
> Compelling opportunity expected to unlock substantial value through enhanced focus, tailored investment and capital allocation, and optimized market valuation > "New BD," built on momentum of BD 2025 strategy, will be well-positioned as a scaled, pure-play Me... - Qureight and Avalyn: Partnership in Pulmonary Fibrosis (2025-02-05)
Qureight Ltd, the Core Imaging Laboratory developing deep-learning image analytics, and Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on developing inhaled therapies to treat life-threatening pulmonary diseases, today announce the initiatio... - HTGF: Akribion Therapeutics Emerges with €8m Seed Round (2025-02-04)
> Financing led by CARMA FUND and RV Invest with participation of High-Tech Gründerfonds and others > Akribion is pioneering a unique, RNA-guided, nuclease-based technology for programmable cell depletion > Experienced team with a background in biotechnology... - Coulter Partners Places Andrew Miles CBO Our Future Health (2025-02-04)
Coulter Partners successfully completed a search assignment for Our Future Health and is pleased to announce the placement of Andrew Miles, as Chief Business Officer (CBO). Our Future Health is an ambitious collaboration between the public, charity and private s... - Evaxion Announces Closing of $10.8m Public Offering (2025-01-31)
Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced the closing of a public offering of an aggregate of 3,997,361 of its American Depositary Shares (“AD... - Rentschler Biopharma to Exit Field of Cell & Gene Therapy (2025-01-30)
Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, announced today a realignment of its global business operations as part of a long-term strategic shift. As part of this realignment, Rentsch...
Life-Sciences-Europe.com is your doorway to the European life sciences!
[LSE] provides free, up-to-date and structured access to
– News
– Products
– Persons
– Organisations
– Financings
– Collaborations
in Europe and Israel.
Access is unrestricted and free, requiring no log in and no user registration.The high-quality content is not related to the advertising, with topical relevance being the criterion for inclusion. [LSE] is 100% Made in Germany!
» Start here with the latest News!Advertisement

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top